Novo says CagriSema linked to 25% mean weight loss among early responders

NVO•2026-11-15

A post hoc analysis of REDEFINE 1 found a 25% mean weight loss among early responders treated with CagriSema. Novo said 67.8% of adults on the investigational 2.4 mg/2.4 mg dose lost at least 5% of their weight by week 8.

Novo says CagriSema linked to 25% mean weight loss among early responders

1. Early response findings

Related News

Brookfield and KKR reportedly vie over $700 million deal for Gulf retailer Eyewa

Nasdaq trade halt continues; reason not available at 03:28 a.m.

Novo Nordisk’s Wegovy linked to reduced food noise in real-world studies

Summit Therapeutics provides update regarding ivonescimab biologics license application

Yemen government forces withdraw from area near Bab el-Mandeb Strait, Houthis in control